Relationship between the severity of alcoholic liver cirrhosis and the metabolism of caffeine in 226 patients
- PMID: 11073287
- DOI: 10.5414/cpp38467
Relationship between the severity of alcoholic liver cirrhosis and the metabolism of caffeine in 226 patients
Abstract
Objectives: To evaluate the polygenic regulated caffeine metabolism in a group of 226 patients with liver alcoholic cirrhosis classified according to the Child score.
Methods: Over a 14-year period an hepatic function test, using caffeine as probe drug, has been systematically associated to the usual clinical and biochemical investigations performed in patients with liver alcoholic cirrhosis. "Caffeine test" consisted in a 200 mg caffeine oral intake. Urines were collected over 24 hours: caffeine (137X), 1-7 dimethylxanthine (17X), 1-3 dimethylxanthine (13X), 1-3 dimethylurate (13U), 3-7 dimethylxanthine (37X), 1-7 dimethylurate (17U), 1-methylxanthine (1X), 1-methylurate (1U), 7-methylxanthine (7X), 3-methylxanthine (3X), and 5-acetylamino-6-formylamino-3-methyluracyl (AFMU) were analyzed by high performance liquid chromatography (HPLC). Total and individual metabolite urinary elimination rates were expressed in micromol/24 hours. Enzyme activities were evaluated from the following urinary metabolites ratios: (AFMU+1U+1X)/17U for CYPIA2, 17U/17X for CYP2A6, AFMU/(AFMU+ 1U+1X) for NAT-2, 1U/1X for XO.
Results: Compared to healthy subjects, whatever the Child score, caffeine metabolism was reduced by half in patients with alcoholic cirrhosis. The main cause was the decreased CYP1A2 activity. On the other hand, XO and CYP2A6 activities were increased and NAT-2 activity remained unchanged in slow acetylators (SA) and decreased in rapid acetylators (RA) Child B and C. Bimodality of NAT-2 distribution was unclear, but a right assignment of RA and SA phenotype in cirrhotic patients, confirmed by comparison with genotype, was obtained, using the antimode value of NAT-2 distribution used in healthy subjects. At last, there was an interindividual variability in caffeine metabolism as great as in the usual laboratory parameters.
Conclusion: Metabolism of caffeine is decreased in patients with alcoholic liver cirrhosis. This decrease paralleled the modifications of the usual laboratory tests and does not bring additional information on the severity of the disease. But the equilibrium between the various metabolic pathways of caffeine is impaired. Beyond the changes of a specific enzymatic activity, this must be taken into account particularly for drugs whose metabolism is of the polygenic regulation type.
Similar articles
-
Caffeine metabolism in a group of 67 patients with primary biliary cirrhosis.Int J Clin Pharmacol Ther. 2001 Jan;39(1):25-32. doi: 10.5414/cpp39025. Int J Clin Pharmacol Ther. 2001. PMID: 11204934
-
Caffeine metabolism before and after liver transplantation.Int J Clin Pharmacol Ther. 2001 Feb;39(2):53-60. doi: 10.5414/cpp39053. Int J Clin Pharmacol Ther. 2001. PMID: 11270802
-
Analysis of urinary caffeine metabolites to assess biotransformation enzyme activities by reversed-phase high-performance liquid chromatography.J Chromatogr B Biomed Sci Appl. 1998 May 8;709(1):27-34. doi: 10.1016/s0378-4347(98)00016-4. J Chromatogr B Biomed Sci Appl. 1998. PMID: 9653923
-
Caffeine metabolic ratios for the in vivo evaluation of CYP1A2, N-acetyltransferase 2, xanthine oxidase and CYP2A6 enzymatic activities.Curr Drug Metab. 2009 May;10(4):329-38. doi: 10.2174/138920009788499003. Curr Drug Metab. 2009. PMID: 19519341 Review.
-
[Progress in the research of caffeine metabolism and its application in vivo].Sheng Li Ke Xue Jin Zhan. 2010 Aug;41(4):256-60. Sheng Li Ke Xue Jin Zhan. 2010. PMID: 21416940 Review. Chinese.
Cited by
-
Nonparametric expectation maximisation (NPEM) population pharmacokinetic analysis of caffeine disposition from sparse data in adult caucasians: systemic caffeine clearance as a biomarker for cytochrome P450 1A2 activity.Clin Pharmacokinet. 2003;42(15):1393-409. doi: 10.2165/00003088-200342150-00006. Clin Pharmacokinet. 2003. PMID: 14674790 Clinical Trial.
-
Can paracetamol (acetaminophen) be administered to patients with liver impairment?Br J Clin Pharmacol. 2016 Feb;81(2):210-22. doi: 10.1111/bcp.12802. Epub 2015 Dec 25. Br J Clin Pharmacol. 2016. PMID: 26460177 Free PMC article. Review.
-
Salivary caffeine metabolic ratio in alcohol-dependent subjects.Eur J Clin Pharmacol. 2004 Apr;60(2):103-7. doi: 10.1007/s00228-004-0734-3. Epub 2004 Mar 12. Eur J Clin Pharmacol. 2004. PMID: 15022032 Clinical Trial.
-
Phenotypic CYP2A6 variation and the risk of pancreatic cancer.JOP. 2009 May 18;10(3):263-70. JOP. 2009. PMID: 19454817 Free PMC article.
-
Hepatic cytochrome P450 enzyme alterations in humans with progressive stages of nonalcoholic fatty liver disease.Drug Metab Dispos. 2009 Oct;37(10):2087-94. doi: 10.1124/dmd.109.027466. Epub 2009 Aug 3. Drug Metab Dispos. 2009. PMID: 19651758 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Medical